Highly Coordinative Substrates in Asymmetric Catalysis
A R T I C L E S
modes displayed by 1.13 To address this issue, we initiated
studies aimed at developing a catalytic asymmetric amination
of 1.14,15 We recently achieved a concise enantioselective
synthesis of (-)-2, in which the catalytic asymmetric amination
of 1 with a lanthanum/amide-based ligand catalyst was a key
step.14,16,17 The amination reaction was scalable, cost-effective,
and the investigations of an industrial application are
underway.14b This article describes the full details of the catalytic
asymmetric amination with the La/amide-based ligand catalyst
system. Based on analyses of the privileged functional group
arrangement of the highly coordinative substrates, the substrate
scope was successfully expanded to other nonprotected sub-
strates, such as N-nonsubstituted R-alkoxycarbonyl amides.
Mechanistic studies suggested that the three components of the
second-generation catalyst were in a dynamic equilibrium and
an associated ternary complex was involved in the transition
state.
Scheme 1. Concise Enantioselective Synthesis of (-)-2
allows for an efficient enantioselective synthesis of AS-
3201((-)-2, ranirestat), a highly potent aldose reductase inhibitor
(Scheme 1). (-)-2 has attracted particular attention because of
its effectiveness for treating diabetic complications via oral
administration.10 Diabetes is one of the most serious health
concerns throughout the world, and the number of patients with
diabetes is rapidly increasing.11 The main focus in the treatment
of diabetes is on decreasing blood glucose levels, and there are
few effective therapeutics for the treatment of late-stage
pathologic conditions that seriously compromise patients’ quality
of life.12 Clinical trials on (-)-2 specifically for diabetic
neuropathy are ongoing, and therapeutic development is highly
anticipated. In this context, an efficient route for the enantiose-
lective synthesis of (-)-2 is in high demand to fulfill a
prospective future supply. Catalytic asymmetric amination of
succinimide derivative 1 emerged as a primary option toward
this end. The Lewis basicity of nonprotected 1, however,
interferes with the efficient enantiodifferentiation by Lewis
acidic chiral catalysts, likely because of the multiple coordination
Results and Discussion
Development of the First-Generation Amination Catalyst.
Our initial effort was devoted to the development of a new class
of catalysts for catalytic asymmetric amination of nonprotected,
highly coordinative succinimide derivative 1. To avoid ligand
dissociation and/or a multiple coordination pattern of 1, we
initially focused on an asymmetric catalyst comprising a rare
earth metal (RE)/amide-based ligand, where the high affinity
of the amide functionality to RE would avoid ligand dissociation
by 1. Taking high coordination number of REs into account, 1
could coordinate to REs surrounded by amide-based ligands and
the hydrogen bonding provided by the ligand could specify the
coordination mode of 1. Three types of amide-based ligands
bearing a phenol functionality for coordination to RE, salicylic
acid-type (S)-3, biphenol-type (S)-4, and hydroxamic acid-type
(S)-5, were examined in the catalytic asymmetric amination of
1 and di-t-butyl azodicarboxylate (Scheme 2). The catalyst was
prepared by mixing the ligand and La(OiPr)3 in a 2:1 ratio. The
catalyst prepared from ligands (S)-3a-d or (S)-4 efficiently
promoted the desired reaction at -40 °C to give (+)-6, whereas
the catalyst prepared from (S)-5 failed the reaction, presumably
because the strongly coordinative hydroxamic acid induced the
formation of a catalytically inactive aggregate. The reaction with
(S)-3a gave the highest enantioselectivity, and further investiga-
tion revealed that lanthanum worked best among the REs tested,
(9) For selected examples using organocatalysts, see: (a) Sabby, S.; Bella,
M.; Jørgensen, K. A. J. Am. Chem. Soc. 2004, 126, 8120. (b) Pihko,
P. M.; Pohjakallio, A. Synlett 2004, 2115. (c) Liu, X.; Li, X.; Deng,
L. Org. Lett. 2005, 7, 167. (d) Xu, X.; Yabuta, T.; Yuan, P.; Takemoto,
Y. Synlett 2006, 137. (e) Terada, M.; Nakano, M.; Ube, H. J. Am.
Chem. Soc. 2006, 128, 16044. (f) Liu, Y.; Melgar-Fernandez, R.;
Juaristi, E. J. Org. Chem. 2007, 72, 1522. (g) Jung, S. H.; Kim, D. Y.
Tetrahedron Lett. 2008, 49, 5527. (h) He, R.; Wang, X.; Hashimoto,
T.; Maruoka, K. Angew. Chem., Int. Ed. 2008, 47, 9466. (i) Lan, Q.;
Wang, X.; He, R.; Ding, C.; Maruoka, K. Tetrahedron Lett. 2009, 50,
3280. (j) Liu, X.; Sun, B.; Deng, L. Synlett 2009, 10, 1685. (k) Cheng,
L.; Liu, L.; Wang, D.; Chen, Y.-J. Org. Lett. 2009, 11, 3874.
(10) (a) Negoro, T.; Murata, M.; Ueda, S.; Fujitani, B.; Ono, Y.; Kuromiya,
A.; Komiya, M.; Suzuki, K.; Matsumoto, J.-I. J. Med. Chem. 1998,
41, 4118. (b) Kurono, M.; Fujiwara, I.; Yoshida, K. Biochemistry 2001,
40, 8216. (c) Bril, V.; Buchanan, R. A. Diabetes Care 2004, 27, 2369.
(d) Kurono, M.; Fujii, A.; Murata, M.; Fujitani, B.; Negoro, T.
Biochem. Pharmacol. 2006, 71, 338. (e) Giannoukakis, N. Curr. Opin.
InVestig. Drugs 2006, 7, 916. (f) Matsumoto, T.; Ono, Y.; Kurono,
M.; Kuromiya, A.; Nakamura, K.; Bril, V. J. Pharmacol. Sci. 2008,
107, 231.
(13) Representative metal catalysts (Cu-BOX, LaPyBox) and organocata-
lysts (chiral urea catalyst, cinchona alkaloids) afforded the desired
product in less than 30% ee (see ref 14a).
(14) (a) Mashiko, T.; Hara, K.; Tanaka, D.; Fujiwara, Y.; Kumagai, N.;
Shibasaki, M. J. Am. Chem. Soc. 2007, 129, 11342. (b) Mashiko, T.;
Kumagai, N.; Shibasaki, M. Org. Lett. 2008, 10, 2725.
(11) (a) Nath, D.; Heemels, M.-T.; Anson, L. Nature 2006, 444, 839. and
the following review articles. (b) International Diabetes Federation
diabetes.asp.
(15) Catalytic asymmetric amination of N-Boc protected 1 was reported
in refs 9h and 9i.
(16) Other examples of asymmetric catalysis using rare earth metal/amide-
based ligand catalysts, see: (a) Nishida, A.; Yamanaka, M.; Nakagawa,
M. Tetrahedron Lett. 1999, 40, 1555. (b) Nitabaru, T.; Kumagai, N.;
Shibasaki, M. Tetrahedron Lett. 2008, 49, 272. (c) Sudo, Y.; Shirasaki,
D.; Harada, S.; Nishida, A. J. Am. Chem. Soc. 2008, 130, 12588. (d)
Nojiri, A.; Kumagai, N.; Shibasaki, M. J. Am. Chem. Soc. 2008, 130,
5630. (e) Nojiri, A.; Kumagai, N.; Shibasaki, M. J. Am. Chem. Soc.
2009, 131, 3779.
(12) For selected examples of the studies toward the treatment of diabetic
complications: Selective PKC ꢀ2 inhibitor for the treatment of diabetic
neuropathy, see: (a) Inoguchi, T.; Battan, R.; Handler, E.; Sportsman,
J. R.; Heath, W.; King, G. L. Proc. Natl. Acad. Sci. U.S.A. 1992, 89,
11059. (b) Ishii, H.; Jirousek, M. R.; Koya, D.; Takagi, C.; Xia, P.;
Clermont, A.; Bursell, S.-E.; Kern, T. S.; Ballas, L. M.; Heath, W. F.;
Stramm, L. E.; Feener, E. P.; King, G. L. Science 1996, 272, 728. (c)
Tanaka, M.; Sagawa, S.; Hoshi, J.-I.; Shimoma, F.; Yasue, K.;
Ubukata, M.; Ikemoto, T.; Hase, Y.; Takahashi, M.; Sasase, T.; Ueda,
N.; Matsushita, M.; Inaba, T. Bioorg. Med. Chem. 2006, 14, 5781,
and references cited therein. Inhibition of vascular endothelial growth
factor (VEGF) for prevention of diabetic microvascular complications,
see: (d) Gemma, T.; Rosangela, L.; Gabriella, M.; Gianpaolo, Z. Am. J.
CardioVasc. Drugs 2007, 7, 393.
(17) For recent selected examples of small peptide-based asymmetric
catalysis, see: (a) Zhao, Y.; Rodrigo, J.; Hoveyda, A. H.; Snapper,
M. C. Nature 2006, 443, 67. (b) Lewis, C. A.; Chiu, A.; Kubryk, M.;
Balsells, J.; Pollard, D.; Esser, C. K.; Murry, J.; Reamer, R. A.; Hansen,
K. B.; Miller, S. J. J. Am. Chem. Soc. 2006, 128, 16454. For reviews,
see: (c) Hoveyda, A. H.; Hird, A. W.; Kacprzynski, M. A. Chem.
Commun. 2004, 1779. (d) Blank, J. T.; Miller, S. J. Biopolymers (Pept.
Sci.) 2006, 84, 38.
9
J. AM. CHEM. SOC. VOL. 131, NO. 41, 2009 14991